Jade Biosciences Statistics
Total Valuation
JBIO has a market cap or net worth of $1.31 billion. The enterprise value is $995.47 million.
Important Dates
The next estimated earnings date is Wednesday, August 12, 2026, after market close.
| Earnings Date | Aug 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
JBIO has 59.36 million shares outstanding.
| Current Share Class | 59.36M |
| Shares Outstanding | 59.36M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +7.01% |
| Owned by Insiders (%) | 0.30% |
| Owned by Institutions (%) | 65.93% |
| Float | 47.74M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 3.66 |
| P/TBV Ratio | 4.41 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 14.29, with a Debt / Equity ratio of 0.00.
| Current Ratio | 14.29 |
| Quick Ratio | 13.96 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -37.11 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -44.96% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.73M |
| Employee Count | 55 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, JBIO has paid $74,000 in taxes.
| Income Tax | 74,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +109.32% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +109.32% |
| 50-Day Moving Average | 21.49 |
| 200-Day Moving Average | 15.00 |
| Relative Strength Index (RSI) | 62.21 |
| Average Volume (20 Days) | 1,702,457 |
Short Selling Information
The latest short interest is 4.95 million, so 8.34% of the outstanding shares have been sold short.
| Short Interest | 4.95M |
| Short Previous Month | 3.16M |
| Short % of Shares Out | 8.34% |
| Short % of Float | 10.36% |
| Short Ratio (days to cover) | 4.37 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -133.60M |
| Pretax Income | -129.54M |
| Net Income | -95.10M |
| EBITDA | n/a |
| EBIT | -133.60M |
| Earnings Per Share (EPS) | -$2.11 |
Full Income StatementBalance Sheet
The company has $311.30 million in cash and $849,000 in debt, giving a net cash position of $310.45 million or $5.23 per share.
| Cash & Cash Equivalents | 311.30M |
| Total Debt | 849,000 |
| Net Cash | 310.45M |
| Net Cash Per Share | $5.23 |
| Equity (Book Value) | 296.46M |
| Book Value Per Share | 6.01 |
| Working Capital | 296.23M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$100.01 million and capital expenditures -$196,000, giving a free cash flow of -$100.21 million.
| Operating Cash Flow | -100.01M |
| Capital Expenditures | -196,000 |
| Depreciation & Amortization | 35,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -100.21M |
| FCF Per Share | -$1.69 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |